The MMP ‐9/ TIMP ‐1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation
Open Access
- 14 October 2025
- journal article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (3) , 442-452
Abstract
Objectives: To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS), and to assess their changes following autologous hematopoietic stem cell transplantation (aHSCT). Methods: CSF samples from pwMS treated with aHSCT ( n = 43) and healthy controls ( n = 32) were analyzed for MMP‐9, TIMP‐1, and OPN concentrations using ELISA and electrochemiluminescence assays. Lumbar punctures were performed at baseline and at 1, 2, and 3–5 years post‐aHSCT. Biomarker findings were compared with standard CSF parameters, prior treatments, and MRI data. Results: MMP‐9/TIMP‐1 ratios and OPN levels were significantly elevated in pwMS compared to controls, particularly in those with gadolinium‐enhancing lesions or on first‐line therapies. Both biomarkers declined significantly after aHSCT and remained low during follow‐up. The MMP‐9/TIMP‐1 ratio showed superior discriminatory capacity and correlated with inflammatory CSF markers. Interpretation: CSF MMP‐9/TIMP‐1 ratio and OPN are elevated in MS and decrease following aHSCT, reflecting reduced inflammation and restored BBB integrity. These biomarkers may support disease monitoring and therapeutic evaluation.Keywords
Funding Information
- Vetenskapsrådet (2021‐02814)
- Marcus och Amalia Wallenbergs minnesfond
- Svenska Sällskapet för Medicinsk Forskning
This publication has 27 references indexed in Scilit:
- Blood‐brain barrier integrity impacts the use of plasma amyloid‐β as a proxy of brain amyloid‐β pathologyAlzheimer's & Dementia, 2023
- Osteopontin associates with brain TRM-cell transcriptome and compartmentalization in donors with and without multiple sclerosisiScience, 2022
- The effect of systemic inflammation on human brain barrier functionBrain, Behavior, and Immunity, 2017
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-β1bMultiple Sclerosis Journal, 2010
- Specificity and Correlation With Disease Activity of Cerebrospinal Fluid Osteopontin Levels in Patients With Multiple SclerosisArchives of Neurology, 2008
- Osteopontin levels and increased disease activity in relapsing–remitting multiple sclerosis patientsJournal of Neuroimmunology, 2004
- Elevated osteopontin levels in active relapsing‐remitting multiple sclerosisAnnals of Neurology, 2003
- The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating DiseaseScience, 2001
- A STUDY OF THE CRYSTALLINE ALBUMIN, GAMMA GLOBULIN AND TOTAL PROTEIN IN THE CEREBROSPINAL FLUID OF ONE HUNDRED CASES OF MULTIPLE SCLEROSIS AND IN OTHER DISEASESThe American Journal of the Medical Sciences, 1950